Human Genome Sciences Reports Progress With Late-Stage Products and New I...(inhalation exposure to massively lethald...),Health

Date:5/28/2008

inhalation exposure to massively lethal doses of anthrax spores. These dramatic and statistically significant findings demonstrate a survival benefit in two animal species, which is the requirement for establishing the efficacy of new drugs used to counter bioterrorism. ABthrax is being developed under contract with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS).

Recent progress: In May 2008, HGS submitted the final data package to BARDA and FDA, which is required to support authorization of delivery to the Strategic National Stockpile. The Company is currently manufacturing ABthrax on schedule to begin delivery of 20,000 doses to the Stockpile by fall 2008. HGS has conducted multiple safety studies of ABthrax in more than 400 adult human volunteers. Final safety follow-up and data collection are underway to support a BLA submission in 2009. Neither the additional safety data nor the BLA submission are required for delivery to the Stockpile.

In June 2006, the U.S. Government exercised its option to purchase 20,000 doses of ABthrax for the Strategic National Stockpile. The purchase award was made under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Stockpile. HGS expects to receive $165 million in revenue from the award. In addition, there is potential for future orders for ABthrax from the U.S. Government or from other governments friendly to the U.S.

Key milestones leading to the Company's first product sales:

-- Begin delivery of ABthrax to the Strategic National Stockpile in fall

2008.

-- Receive $100-120 million in revenues in late 2008.

INVESTMENT IN NEW INITIATIVES TO BUILD THE HGS PIPELINE

Oncology Portfolio: A Key Driver of Future Growth

As the Company's late-stage products are nearing commercialization, HGS is inve
'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent